Direct-to-Consumer Generic Drugs: A Maverick Approach or Another Exposure of Market Failures?

Ann Intern Med. 2022 Jun;175(6):890-891. doi: 10.7326/M22-0740. Epub 2022 Apr 19.

Authors

Hussain S Lalani¹, Aaron S Kesselheim¹, Benjamin N Rome¹

Affiliation

¹ Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (H.S.L., A.S.K., B.N.R.).

PMID: 35436150
DOI: 10.7326/M22-0740

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Drug Costs*
Drug Industry
Drugs, Generic*
Economic Competition
Humans

Substances

Drugs, Generic